Chiron Corporation

Ortho-clinical Diagnostics, Inc

Novartis Vaccines & Diagnostics, Gmbh

F. Hoffmann-la Roche Ag

Grifols Worldwide Operations Limited

Grifols Diagnostic Solutions Inc.

John Andrew Hall

Angelica Medina-Selby

Doris Guenzi Coit

Stephen David Harrison

Maria Calderon-Cacia

Ziyang Zhong

Steve H Nguyen

Eric Y Fang

Michael Houghton

George Kuo

Kent B Thudium

Frank I Marcus

Robert O Ralston

Barbara A Gervase

Kim M Berger

Qui-Lim Choo

David Y Chien

Jian Zheng

Alexander Gyenes

Jody Berry

Elizabeth Booth

Toshiya Fujihara

Peter Schwind

Matteo Binda

Vincenzo Favaloro

Oui-Lim Choo

Virginia Montanini

Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ib&#x3b1; that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

Composition comprising recombinant GPlb&#x3b1; receptor protein

A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.

Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain

Modified hepatitis C virus polypeptides are described. The polypeptides include the HCV NS4a domain and modified NS3 domain. The polypeptides retain conformational epitopes. HCV immunoassays including the polypeptides are also described.

HCV NS4a/modified NS3 polypeptides and uses thereof

HCV NS4A/modified NS3 polypeptides and uses thereof

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&#x3b1; and GSK3&#x3b2; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

GSK3 polypeptides

Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.

Antibodies to hepatitis C virus asialoglycoproteins

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

Hepatitis C virus asialoglycoproteins

Growing community of inventors

Rohnert Park, CA, United States of America

John Andrew Hall